A particularly exciting research paper catches your eye. You start to read it in detail, carefully studying the methods, figures, data and logic. To your growing horror, you realize that a few of the blots and gel images look as though they have been digitally manipulated. You immediately inform the journal of your suspicions and are told that the editors will 'look into it' . But after months of silence, you begin to wonder if that phrase is just a euphemism for inaction.
It isn't -certainly not at Nature or any of the other Nature-branded journals. We make a concerted effort to forestall such problems by spot-checking the images in at least two papers of each issue before publication. Even so, Nature journals that publish a substantial number of gels and blots still receive up to five reports of image manipulation per journal per year -and few of these cases can be handled quickly.
When we receive a complaint, we first do our own tests on the figures to see whether the charges have merit. We also take a careful look at the paper as a whole. Some claims of fraudulent image manipulation turn out to be mistaken. Others we suspect of being clumsy attempts to slur the reputations of others.
Occasionally, our examination suggests that something may be amiss. We then ask the authors for the original data and an explanation of what has happened. This is to help us understand whether the images really were manipulated and, if so, why. This request for authors to provide us with explanations holds true for almost all other types of allegations, from authors not sharing materials as expected to charges of fabricated data or plagiarism.
Intent is key -we often find that no data have been fabricated, but that poor practice and a lack of education have allowed unexplained gel splices, for example, to slip past co-authors before submission or during the revision process. Taking into account the authors' response, together with our comparison of the original images with the published figures, we will hopefully find that the apparent problems are either nonexistent or easily remedied. If we conclude otherwise, we will then contact the authors' home institution. This step is necessary because, unlike universities and other such institutions, journals don't have the resources or the legal authority to investigate allegations fully, or to make formal findings of research misconduct.
At Nature, we usually wait for the results of a formal inquiry before correcting the record -hence the seeming inaction. Institutions vary in their practices, and some are more efficient than others. Institutions that accept government grants in the United States must have a researchintegrity officer to handle such allegations, but they are not obliged to share their information with us. We urge institutions to produce a redacted version of their final report that protects the innocent, but that indicates the extent of the investigation and the findings on each allegation. Because this is not general practice, we are not always sure that we concur with the actions suggested by the institution's investigating committee. To see exactly what was examined, we are forced to request clarifications, which delays revisions to the public record further.
Time to adapt
A new generation of clinical trials could yield breakthroughs, but must be handled with care.
A t the American Association for Cancer Research annual meeting in Washington DC last week, a recurrent theme was complexity. The deeper scientists have delved into the fundamental nature of cancer, the more they have come to recognize its vast genetic diversity, which can make even tumours of the same cancer type seem unrelated.
It is encouraging to see researchers embracing new methods to deal
At times, we have to resort to the US Freedom of Information Act to obtain enough information to correct the literature appropriately. If the institute is not in the United States, lines of responsibility are less clear. Determining whom to contact is not straightforward and convincing parties that an investigation is needed and getting useful information back is not a reliable process. Sometimes, this means it can be difficult to judge if the investigation has been thorough and fair.
The complexity of a case, which is not always readily apparent, also has a bearing on how quickly a verdict can be reached. If an institution's report concludes that misconduct occurred, we usually insist on a retraction -and will issue the retraction ourselves if the authors refuse to comply. But when an institution's investigation cites lesser problems such as 'beautification' of the images, 'sloppy science' or 'inadequate record-keeping' -sometimes misconduct is suspected but cannot be proven -we will base our response on the specifics of the case.
If there were no data fraud and no intent to deceive, for example, and if only one or two images were involved, we would allow the authors to publish an erratum and supply appropriate data, figures, original gels or images as supplementary information. Such an erratum can enhance the authors' reputation for honesty. But if most of the figures are problematic, we will strongly urge the authors to retract the paper, even if they were cleared of misconduct and even if the paper's main conclusions have been verified independently by other labs. The logic is that the published paper did not accurately reflect the data as they were collected.
We urge all readers or reviewers who think that images or other information have been inappropriately handled to bring your concerns to the attention of the editors. By doing so you help increase the reliability of the literature, and so prevent the waste of both time and money following up fraudulent leads and fabricated insights. We strongly believe that it is in our best interest to correct errors that we have published, once we have as much information as we are likely to get -a practice that all journals should embrace.
with that complexity. One especially promising technique highlighted in several talks was the 'adaptive' clinical trial, which allows researchers to avoid being locked into a single, static protocol for the duration of the trial. Instead, investigators can evaluate data as they come in, and use that information to change a trial's structure (see page 1258).
Such flexibility is particularly important in cancer research. Investigators have struggled to plan clinical trials that can incorporate an ever-proliferating list of molecular biomarkers -features such as mutations or gene-expression patterns that can be used to distinguish one person's tumour from the next person's. The idea is to find markers that can identify a subset of people for which a given therapy is working, even when it seems to have little effect on the patient population as a whole. Adaptive trials thus allow investigators to analyse the data midstream, correlate those results with known biomarkers, and then alter the course of the trial in light of that information -perhaps by enrolling additional people with cancer on the basis of their biomarker status. The trial then continues, targeting those people most likely to benefit.
Researchers have dabbled with such experiments for years. But it was only in 2007 that the European Medicines Agency (EMA) published a paper outlining appropriate adaptive-trial conduct, and only in February 2010 that the US Food and Drug Administration (FDA) followed suit with its draft guidance to industry. The FDA draft is open for public comment until 1 June.
Guidance from these key agencies is likely to spur interest in the trials, but it will take more than that to fully exploit the technique's potential. Because adaptive trials require more statistical sophistication than conventional ones, for example, medical researchers will have to work with statisticians on trial design from the outset. And because the trials require extra months of planning time, pharmaceutical companies will have to revise the common practice of financially rewarding the speed with which a clinical-trial team enrols its first patient, to avoid tempting researchers to shortcut the planning.
And there are potential pitfalls with adaptive trials. Perhaps most importantly, researchers who use adaptive techniques will have to take care that they do not fool themselves. By changing the patient population to one that is more likely to benefit from the treatment, they can inflate the risk of reaching a false-positive conclusion. They also run the risk that the interim data required to take that step might compromise a trial's double-blind safeguards, influence patient and investigator behaviour, and colour the results even further. For these reasons, the FDA and the EMA advise against using an adaptive trial when a standard trial will do, and urge extra caution in designing the late-stage clinical trials that are crucial to determining drug approvals.
The two documents also outline the statistical methods that can be used to control the false-positive rate, and call for appointing an independent body to handle the interim review. But these guidelines cannot be taken as the final word. Undertaking adaptive clinical trials is an experiment in itself: there is much still to be learned about the unforeseen pitfalls, and what the best practices are. As always in science, investigators must be ready to adapt their approaches as the data come in.
■

Security first
Scientists must be more proactive in encouraging good cybersecurity practices.
M ost scientists, like most Internet users, probably think of cybercrime as a misfortune that happens to others -to banks, say, or to online retailers who are careless with customers' credit-card information, or to individuals who fall for a getrich-quick e-mail from Nigeria.
But the unsettling truth is that academic institutions are among hackers' prime targets. Not only do campuses tend to be richly supplied with personal computers, servers and other computing resources, but they are connected to the world by highbandwidth networks and populated by inexperienced, casual and sometimes reckless students (see page 1260). This wide-open computational environment is ripe for being co-opted, whether it is to send out spam, run illegal file-sharing sites or launch further cyberattacks.
Worse, from researchers' point of view, is that much -if not all -of their hard-won laboratory data live in that environment, where the information is vulnerable to theft and malicious damage. Computer security has moved up the agenda of universities and other research institutions over the past decade, and most places now have teams of professionals to monitor suspicious traffic and maintain a safe environment. But such structured, centralized efforts can result in controls that raise scientists' hackles and violate their impulse to do things their own way. As a result, too many researchers set up their own computer systems and ignore any security help the university's professionals can give them.
This attitude is unhelpful, bordering on reckless. University information-technology administrators do need to manage things with as light and as unobtrusive a hand as possible -for example, by making sure that researchers retain the freedom to use the software they choose. But laboratories, especially the smaller ones, need to avail themselves of the professionals' skills as much as possible.
Larger research projects with heavy data needs may have the resources to exercise more autonomy. But even so, it is imperative that such projects put a qualified person in charge of cybersecurity who can take sole responsibility for keeping up with the fast-moving requirements that security issues present.
Large group or small, the ultimate responsibility for protecting data and other resources has to rest with the laboratories that own them. Every lab director must be aware of the risks, and must treat cybersecurity with the same respect as laboratory safety, patient safety and scientific integrity. 
